Pricing Log in Create free account

Altimmune, Inc. (ALT) vs Editas Medicine, Inc. (EDIT)

Altimmune, Inc. and Editas Medicine, Inc. are both Biotechnology companies. Altimmune, Inc. and Editas Medicine, Inc. are of similar size ($399.3M and $396.8M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against 20.8%. Altimmune, Inc. has the higher net margin (0.00% vs −157.3%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 17 metrics below, Altimmune, Inc. leads on 9 and Editas Medicine, Inc. on 8.

Valuation

Metric ALT EDIT Biotechnology median
P/E n/m n/m 10.64
P/S 8,224.03 6.60 9.59
P/B 0.80 2.95 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 1,889.09 2.79 9.45
Earnings yield (38.24%) (28.85%) (34.69%)
Free cash flow yield (20.29%) (38.78%) (24.02%)

Profitability

Metric ALT EDIT Biotechnology median
Gross margin 100.00% 100.00% 65.59%
Operating margin 0.00% (161.39%) 0.00%
Net margin 0.00% (157.32%) 0.00%
Free cash flow margin 0.00% (255.88%) 0.00%
Return on equity (28.87%) (118.82%) (51.96%)
Return on assets (25.58%) (33.02%) (46.06%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT EDIT Biotechnology median
Revenue growth (TTM) 130.00% 20.83% 4.59%
EPS growth (last fiscal year) 25.37% 37.50% 29.88%
Revenue growth, 5-year CAGR (65.33%) (14.89%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT EDIT Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 26.78 3.19 4.86
Net debt to EBITDA 2.49 0.94 1.01

Dividend

Metric ALT EDIT Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ALT EDIT Biotechnology median
Market cap 396.82m 399.31m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack